Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Receivables - Net: 2015-2024

Historic Receivables - Net for Cartesian Therapeutics (RNAC) over the last 9 years, with Dec 2024 value amounting to $872,000.

  • Cartesian Therapeutics' Receivables - Net fell 85.05% to $722,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $722,000, marking a year-over-year decrease of 85.05%. This contributed to the annual value of $872,000 for FY2024, which is 85.14% down from last year.
  • According to the latest figures from FY2024, Cartesian Therapeutics' Receivables - Net is $872,000, which was down 85.14% from $5.9 million recorded in FY2023.
  • Cartesian Therapeutics' 5-year Receivables - Net high stood at $9.9 million for FY2021, and its period low was $872,000 during FY2024.
  • For the 3-year period, Cartesian Therapeutics' Receivables - Net averaged around $4.4 million, with its median value being $5.9 million (2023).
  • Its Receivables - Net has fluctuated over the past 5 years, first skyrocketed by 44.48% in 2020, then tumbled by 85.14% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Receivables - Net (Yearly) stood at $7.2 million in 2020, then spiked by 37.24% to $9.9 million in 2021, then crashed by 33.47% to $6.6 million in 2022, then fell by 11.01% to $5.9 million in 2023, then tumbled by 85.14% to $872,000 in 2024.